In the era of precision medicine, RNA Sequencing (RNA-Seq) has transcended its origins as a basic research tool to become a cornerstone of clinical diagnostics. Unlike DNA sequencing, which provides a static blueprint of the genome, RNA sequencing offers a dynamic view of gene expression, capturing the "real-time" functional state of cells. As a premier CE Certified RNA Sequencing Platforms Manufacturer, we recognize that the demand for these systems is driven by their ability to identify biomarkers, understand disease mechanisms, and guide therapeutic interventions.
The global genomics market is currently witnessing a transition from high-cost, centralized sequencing models to more accessible, distributed platforms. This "democratization of sequencing" requires hardware that is not only high-throughput but also highly reliable and compliant with international standards like CE-IVD (In Vitro Diagnostics).
Modern platforms must now support integrated workflows, combining RNA-seq with DNA and protein analysis to provide a holistic view of biological systems.
Capturing low-abundance transcripts is critical for early cancer detection and rare disease research. Our platforms utilize advanced signal processing to ensure maximum sensitivity.
The "bottleneck" is no longer just the sequencing, but the data analysis. Our systems offer automated, cloud-compatible pipelines for immediate insight generation.
Based in the global technology hub of Shenzhen, China, our manufacturing ecosystem provides an unparalleled advantage for international clients. Shenzhen BioX Medical Co., Ltd. operates a state-of-the-art facility spanning over 9,000 square meters, optimized for the precision assembly of molecular diagnostic systems.
The concentration of the medical device supply chain in Shenzhen allows for rapid prototyping, significantly reduced lead times, and competitive cost structures without sacrificing quality. Our integration with local component manufacturers—from high-precision optical lenses to advanced robotic arms—ensures that our RNA sequencing platforms remain at the cutting edge of technological feasibility.
Navigating the regulatory landscape is often the largest hurdle for clinical laboratories. As a CE Certified Manufacturer, we ensure that every unit leaving our floor meets the rigorous safety and performance standards of the European Economic Area. But compliance is just the beginning.
Guarantees that our platforms are suitable for diagnostic use, meeting essential requirements for safety, precision, and clinical evidence.
We provide software interfaces and technical manuals in multiple languages, ensuring seamless integration into local healthcare infrastructures.
Our global network of engineers offers specialized training for lab technicians, focusing on workflow optimization and preventive maintenance.
Procurement departments in hospitals and research institutes have shifted their focus from "lowest price" to "total cost of ownership (TCO)" and "supply chain resilience." Our platforms are designed to address these specific needs:
Using RNA-seq for fusion gene detection and tumor mutational burden (TMB) analysis in clinical oncology departments.
Rapid pathogen identification and antimicrobial resistance (AMR) profiling in public health laboratories.
Optimizing crop yields and disease resistance through transcriptome analysis in regional agricultural research centers.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
The company's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
Supported by a multidisciplinary team of engineers, laboratory specialists, and quality management professionals, the company continuously invests in innovation and product development. Comprehensive quality control procedures are implemented throughout design, manufacturing, testing, and inspection processes to ensure consistent performance and compliance with international industry standards.
CE marking indicates that the product complies with EU safety, health, and environmental protection requirements. For RNA sequencing platforms used in clinics, it often refers to the IVD (In Vitro Diagnostic) directive, ensuring the device is safe and effective for patient diagnosis.
We implement a total quality management system (TQM) including ISO 13485 certification. Every unit undergoes rigorous testing for optical precision, thermal stability, and computational accuracy before shipment.
Yes, we offer extensive OEM and ODM services. This includes hardware modifications, custom firmware development, and branding for distributors and large-scale clinical enterprises.
Due to our robust supply chain in Shenzhen, standard orders typically ship within 4-6 weeks. Custom OEM projects vary based on complexity but benefit from our localized rapid prototyping capabilities.
Our platforms come with integrated secondary analysis software. We also offer consulting for tertiary analysis and integration with common cloud-based genomic platforms.
BioX Medical
